13 March 2018 - The use of new drugs to treat breast cancer and Hodgkin’s lymphoma has been approved, bringing Scottish health services in line with England. 

The Scottish Medicines Consortium, an NHS advisory body, has accepted ribociclib (trade name Kisqali) for advanced breast cancer in postmenopausal women while pembrolizumab (Keytruda) was accepted for advanced Hodgkin’s lymphoma in patients who have failed to respond to previous treatments. 

However, the consortium rejected the use of atezolizumab (Tecentriq) for advanced bladder cancer in patients unable to receive the present preferred treatment because of “uncertainties in the evidence”.

Read The Times article